Barinthus Biotherapeutics(BRNS)

Focus: Barinthus is a public-stage biotech focused on T cell immunotherapy for vaccines and infectious diseases, headquartered in Germantown, MD. The company operates a lean pipeline spanning influenza, HPV, hepatitis B, and oncology indications.

Infectious Diseases Vaccines

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Barinthus Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Barinthus Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$15M

Pipeline & Clinical Trials

VTP-1000

Celiac Disease

Phase 1

Clinical Trials (1)

NCT06310291VTP-1000 in Adults With Celiac Disease

Phase 1

Help build intelligence for Barinthus Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and potential upside if pipeline candidates advance to Phase 3
Leading position in T cell immunotherapy and viral vector vaccine platforms offers cutting-edge technical exposure
Early-stage pipeline (Phase 1/2 dominant) creates opportunities to shape clinical development strategies

Watch Out For

No active job openings at time of data collection signals minimal hiring or potential organizational strain
Substantial R&D burn ($42M in FY2025) against minimal revenue ($15M) creates short runway; $111M cash supports ~2.6 years at current burn rate without additional revenue
Zero Phase 3 programs and no approved products mean no near-term revenue catalysts or commercial infrastructure

Generated by Claude from Barinthus Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ChAdOx1-MVA 5T4

Prostate Cancer

Phase 1/2

ChAdOx1-PCAQ

Prostate Cancer

Phase 1/2

Clinical Trials (1)

NCT05617040Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Phase 1/2

ChAdOx1-HPV

HPV Infection

Phase 1/2

Clinical Trials (1)

NCT04607850Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Phase 1/2

ChAdOx1-HBV

Hepatitis B

Phase 2

Clinical Trials (3)

NCT05343481Efficacy of VTP-300 in Chronic Hepatitis B Infection

Phase 2

NCT04778904First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

Phase 1/2

NCT04297917First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection

Phase 1

MVA-NP+M1

Influenza

Phase 2

Clinical Trials (2)

NCT03883113Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Phase 2

NCT03880474Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Infectious Diseases, Gastroenterology, Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

5 pipeline

Gastroenterology

1 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$15M1766%

R&D Spend

$42M(282%)6%

Net Income

-$61M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles